FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Niels Andreasen

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Enzyme-Linked Immunosorbent Assay

Phenomena

Phosphorylation

Physiology

Genes & Molecular Sequences

Single Nucleotide Polymorphism

Co-author Network

Publications

TOP 3
Xiaozhen Li; Niels Andreasen; Tie-Qiang Li; Eric Westman; Maria Kristoffersen Wiberg; Lars-Olof Wahlund
Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD.
Bob Olsson; Henrik Zetterberg; Niels Andreasen; Peter Annas; Hans Basun; Kaj Blennow; Joakim Hertze; Kina Höglund; Lars Lannfelt; Lennart Minthon; Katarina Nägga; Mattias Ohlsson; Oskar Hansson
Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
Bob Olsson; Henrik Zetterberg; Niels Andreasen; Peter Annas; Hans Basun; Kaj Blennow; Joakim Hertze; Kina Höglund; Lars Lannfelt; Ronald Lautner; Lennart Minthon; Katarina Nägga; Oskar Hansson
Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Niels Andreasen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Xiaozhen Li; Niels Andreasen; Tie-Qiang Li; Eric Westman; Maria Kristoffersen Wiberg; Lars-Olof Wahlund
Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD.
Scientific reports 2013;3():1339.
2013: Bob Olsson; Henrik Zetterberg; Niels Andreasen; Peter Annas; Hans Basun; Kaj Blennow; Joakim Hertze; Kina Höglund; Lars Lannfelt; Lennart Minthon; Katarina Nägga; Mattias Ohlsson; Oskar Hansson
Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
Journal of Alzheimer's disease : JAD 2013;34(3):673-9.
2013: Bob Olsson; Henrik Zetterberg; Niels Andreasen; Peter Annas; Hans Basun; Kaj Blennow; Joakim Hertze; Kina Höglund; Lars Lannfelt; Ronald Lautner; Lennart Minthon; Katarina Nägga; Oskar Hansson
Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.
Journal of Alzheimer's disease : JAD 2013;33(1):45-53.
2012: Alina Solomon; Anders Wimo; Ulrika Akenine; Niels Andreasen; Vesna Jelic; Miia Kivipelto; Francesca Mangialasche; Bengt Winblad
Practical lessons from amyloid immunotherapy trials in Alzheimer disease.
Current Alzheimer research 2012;9(10):1126-34.
2012: Vladimir Coric; Randy Dockens; Howard H Feldman; Chahin Pachai; Gary Pilcher; Erik Portelius; Ralph W Richter; Linda Rollin; Stephen Salloway; Thomas Shiovitz; Holly Soares; Hilkka Soininen; Stephen Thein; Christopher H van Dyck; Charles Albright; Niels Andreasen; Ulf Andreasson; Kaj Blennow; Mark Brody; Susan Colby; Robert M Berman
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Archives of neurology 2012;69(11):1430-40.
2012: Bengt Winblad; Niels Andreasen; Kaj Blennow; Thomas Dumortier; Annette Floesser; Georges Imbert; Joens Lundmark; R Paul Maguire; Lennart Minthon; Jean-Marc Orgogozo; Matthias Staufenbiel; Ana Graf
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
Lancet neurology 2012;11(7):597-604.
2012: Sara Landgren; Jan Marcusson; Lennart Minthon; Staffan Nilsson; Mona Seibt Palmér; Ingmar Skoog; Malin von Otter; Anders Wallin; Henrik Zetterberg; Caroline Zetterström; Niels Andreasen; Kaj Blennow; Nenad Bogdanovic; Deborah R Gustafson; Petronella Kettunen
A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2012;119(7):833-42.
2012: Christoffer Rosén; Niels Andreasen; Ulf Andreasson; Kaj Blennow; Jan Marcusson; Niklas Mattsson; Lennart Minthon; Henrik Zetterberg
Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
Neuromolecular medicine 2012;14(1):65-73.
2012: N Mattsson; Lennart Minthon; E Mulugeta; M Olde Rikkert; Lucilla Parnetti; K Rich; E Rosén; Philip scheltens; J Schröder; M Tsolaki; Wiesje M van der Flier; M M Verbeek; P J Visser; A Wallin; B Winblad; Dag Aarsland; Niels Andreasen; Marinus A Blankenstein; K Blennow; M de Leon; M Eriksdotter-Jönhagen; Michael Ewers; H Hampel; Oskar Hansson; Sanna-Kaisa Herukka; M Jonsson; E Kaiser; J Marcusson; Henrik Zetterberg
Age and diagnostic performance of Alzheimer disease CSF biomarkers.
Neurology 2012;78(7):468-76.
2012: Bob Olsson; Henrik Zetterberg; Kina Höglund; Lars Lannfelt; Clas Malmeström; Niels Andreasen; Peter Annas; Hans Basun; Kaj Blennow
Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials.
Journal of Alzheimer's disease : JAD 2012;32(2):273-6.
2012: Maria Eriksdotter-Jönhagen; Vesna Jelic; Ahmadul Kadir; Göran Lind; Bengt Linderoth; Agneta Nordberg; Ake Seiger; Erik Sundström; Layth Aladellie; Ove Almkvist; Per Almqvist; Niels Andreasen; Kaj Blennow; Nenad Bogdanovic; Lars-Olof Wahlund; Anders Wall; Maria Wiberg; Bengt Winblad; Lars Wahlberg
Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.
Dementia and geriatric cognitive disorders 2012;33(1):18-28.
2012: Taher Darreh-Shori; Malahat Mousavi; Niels Andreasen; Manar Siawesh; Agneta Nordberg
Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Journal of Alzheimer's disease : JAD 2012;28(2):443-58.
2011: Taher Darreh-Shori; Anton Forsberg; Chelenk Kamil; Bengt Långström; Negar Modiri; Hiba Ahmed; Ove Almkvist; Niels Andreasen; Kaj Blennow; Agneta Nordberg
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Neurobiology of aging 2011;32(12):2320.e15-32.
2011: Erik Jedenius; Kristina Johnell; Jan Strömqvist; Bengt Winblad; Johan Fastbom; Niels Andreasen
Dementia management programme in a community setting and the use of psychotropic drugs in the elderly population.
Scandinavian journal of primary health care 2011;29(3):181-6.
2011: Miia Kivipelto; Alina Solomon; Dag Aarsland; Niels Andreasen; Vesna Jelic; Gunilla Johansson; Bengt Winblad
[New criteria for Alzheimer disease. Use of biological markers for earlier and more precise diagnosis].
Läkartidningen 2011;108(32-33):1491-2.
2011: Lucilla Parnetti; Vincenzo Talesa; A K Wallin; Henrik Zetterberg; D Chiasserini; C Hüls; L Minthon; M Ohlson; Niels Andreasen; U Andreasson; Kaj Blennow
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Acta neurologica Scandinavica 2011;124(2):122-9.
2011: Taher Darreh-Shori; Chelenk Kamil; Negar Modiri; Hiba Ahmed; Niels Andreasen; Souad Baza; Kaj Blennow; agneta nordberg
The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
Neurobiology of aging 2011;32(7):1236-48.
2011: Thiemo Rudolph; Annica Sjölander; Mona Seibt Palmér; Lennart Minthon; Anders Wallin; Niels Andreasen; Gunnar Tasa; Erkki Juronen; Kaj Blennow; Henrik Zetterberg; Madeleine Zetterberg
Ubiquitin carboxyl-terminal esterase L1 (UCHL1) S18Y polymorphism in patients with cataracts.
Ophthalmic genetics 2011;32(2):75-9.
2011: Kaj Blennow; M Jonsson; Niels Andreasen; Lars Rosengren; Anders Wallin; P A Hellström; Henrik Zetterberg
No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons.
Acta neurologica Scandinavica 2011;123(4):245-51.
2011: Sonia Chalbot; Tormod Fladby; Inge Grundke-Iqbal; Niels Andreasen; Kaj Blennow; Henrik Zetterberg; Khalid Iqbal
Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease.
Journal of Alzheimer's disease : JAD 2011;25(3):505-15.
2010: Annika Thorsell; Maria Bjerke; Johan Gobom; Eva Brunhage; Eugeen Vanmechelen; Niels Andreasen; Oskar Hansson; Lennart Minthon; Henrik Zetterberg; Kaj Blennow
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.
Brain research 2010;1362():13-22.
2010: K Wesnes; Chris Edgar; Niels Andreasen; P Annas; H Basun; Lars Lannfelt; Henrik Zetterberg; Kaj Blennow; L Minthon
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Acta neurologica Scandinavica 2010;122(4):270-7.
2010: Malin von Otter; Sara Landgren; Staffan Nilsson; Caroline Lundvall; Lennart Minthon; Nenad Bogdanovic; Niels Andreasen; Deborah R Gustafson; Ingmar Skoog; Anders Wallin; Anna Zettergren; Hans Nissbrandt; Madeleine Zetterberg; Gunnar Tasa; Kaj Blennow; Henrik Zetterberg
Kinesin light chain 1 gene haplotypes in three conformational diseases.
Neuromolecular medicine 2010;12(3):229-36.
2010: Sara Landgren; Mona Seibt Palmér; Ingmar Skoog; Lennart Minthon; Anders Wallin; Niels Andreasen; Madeleine Zetterberg; Kaj Blennow; Henrik Zetterberg
No association of VEGF polymorphims with Alzheimer's disease.
Neuromolecular medicine 2010;12(3):224-8.
2010: Erik Jedenius; Anders Wimo; Jan Strömqvist; Linus Jönsson; Niels Andreasen
The cost of diagnosing dementia in a community setting.
International journal of geriatric psychiatry 2010;25(5):476-82.
2010: E H Wiig; P Annas; H Basun; Niels Andreasen; Lars Lannfelt; Henrik Zetterberg; Kaj Blennow; L Minthon
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
Acta neurologica Scandinavica 2010;121(3):186-93.
2010: Malin von Otter; Sara Landgren; Staffan Nilsson; Madeleine Zetterberg; Dragana Celojevic; Petra Bergström; Lennart Minthon; Nenad Bogdanovic; Niels Andreasen; Deborah R Gustafson; Ingmar Skoog; Anders Wallin; Gunnar Tasa; Kaj Blennow; Michael Nilsson; Ola Hammarsten; Henrik Zetterberg
Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract.
Mechanisms of ageing and development 2010;131(2):105-10.
2010: Niels Andreasen; Kaj Blennow; Henrik Zetterberg
Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease.
International journal of Alzheimer's disease 2010;2010():638379.
2010: Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.
International journal of Alzheimer's disease 2010;2010():.
2010: Madeleine Zetterberg; Annica Sjölander; Malin von Otter; Mona Seibt Palmér; Sara Landgren; Lennart Minthon; Anders Wallin; Niels Andreasen; Kaj Blennow; Henrik Zetterberg
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease.
Molecular neurodegeneration 2010;5():11.
2009: Lutz Froelich; Niels Andreasen; Magda Tsolaki; Arnaud Foucher; Shane Kavanagh; Bart Van Baelen; Susanne Schwalen
Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey.
Current medical research and opinion 2009;25(12):3059-68.
2009: Alina Solomon; Valerio Leoni; Miia Kivipelto; Ariadna Besga; Anne Rita Oksengård; Per Julin; Leif Svensson; Lars-Olof Wahlund; Niels Andreasen; Bengt Winblad; Hilkka Soininen; Ingemar Björkhem
Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.
Neuroscience letters 2009;462(1):89-93.
2009: Niklas Mattsson; Henrik Zetterberg; Oskar Hansson; Niels Andreasen; Lucilla Parnetti; Michael Jonsson; Sanna-Kaisa Herukka; Wiesje M van der Flier; Marinus A Blankenstein; Michael Ewers; Kenneth Rich; Elmar Kaiser; Marcel Verbeek; Magda Tsolaki; Ezra Mulugeta; Erik Rosén; Dag Aarsland; Pieter Jelle Visser; Johannes Schröder; Jan Marcusson; Mony de Leon; Harald Hampel; Philip scheltens; Tuula Pirttilä; Anders Wallin; Maria Eriksdotter Jönhagen; Lennart Minthon; Bengt Winblad; Kaj Blennow
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
JAMA : the journal of the American Medical Association 2009;302(4):385-93.
2009: Henrik Zetterberg; Niels Andreasen; Kaj Blennow
[Biomarkers in cerebrospinal fluid and blood in memory complaints].
Läkartidningen 2009;106(20):1386-9.
2009: Lennart Minthon; Anders Wallin; S Eriksson; C Wattmo; Niels Andreasen
Long-term rivastigmine treatment in a routine clinical setting.
Acta neurologica Scandinavica 2009;119(3):180-5.
2009: Annika Ohrfelt; Pierre Grognet; Niels Andreasen; Anders Wallin; Eugeen Vanmechelen; Kaj Blennow; Henrik Zetterberg
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Neuroscience letters 2009;450(3):332-5.
2009: Peder Buchhave; Kaj Blennow; Henrik Zetterberg; Erik Stomrud; Elisabet Londos; Niels Andreasen; Lennart Minthon; Oskar Hansson
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
PloS one 2009;4(7):e6294.
2009: Sara F Hansson; Ulf Andréasson; Mariann Wall; Ingmar Skoog; Niels Andreasen; Anders Wallin; Henrik Zetterberg; Kaj Blennow
Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
Journal of Alzheimer's disease : JAD 2009;16(2):389-97.
2008: Jin-Moo Lee; Kaj Blennow; Niels Andreasen; Omar Laterza; Vijay Modur; Jitka Olander; Feng Gao; Matt Ohlendorf; Jack H Ladenson
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients.
Clinical chemistry 2008;54(10):1617-23.
2008: Christin Andersson; Kaj Blennow; Ove Almkvist; Niels Andreasen; Peter Engfeldt; Sven-Erik Johansson; Maria Lindau; Maria Eriksdotter-Jönhagen
Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
Neurobiology of aging 2008;29(10):1466-73.
2008: Madeleine Zetterberg; Sara Landgren; Malin E Andersson; Mona Seibt Palmér; Deborah R Gustafson; Ingmar Skoog; Lennart Minthon; Dag Steinar Thelle; Anders Wallin; Nenad Bogdanovic; Niels Andreasen; Kaj Blennow; Henrik Zetterberg
Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2008;147B(6):720-6.
2008: A H Simonsen; James McGuire; Vladimir N Podust; H Davies; Lennart Minthon; Ingmar Skoog; Niels Andreasen; Anders Wallin; Gunhild Waldemar; Kaj Blennow
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.
Neurobiology of aging 2008;29(7):961-8.
2008: Ahmadul Kadir; Niels Andreasen; Ove Almkvist; Anders Wall; Anton Forsberg; Henry Willy Engler; Göran Hagman; Marie Lärksäter; Bengt Winblad; Henrik Zetterberg; Kaj Blennow; Bengt Långström; agneta nordberg
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
Annals of neurology 2008;63(5):621-31.
2008: Erik Jedenius; Anders Wimo; Jan Strömqvist; Niels Andreasen
A Swedish programme for dementia diagnostics in primary healthcare.
Scandinavian journal of primary health care 2008;26(4):235-40.
2008: Niels Andreasen; Henrik Zetterberg
Amyloid-related biomarkers for Alzheimer's disease.
Current medicinal chemistry 2008;15(8):766-71.
2007: Michael Ewers; Katharina Buerger; Stefan J Teipel; Philip scheltens; J Schröder; Raymond Zinkowski; Femke H Bouwman; Peter Schönknecht; Niki S M Schoonenboom; Niels Andreasen; Anders Wallin; John DeBernardis; Daniel Kerkman; Bernhard Heindl; Kaj Blennow; Harald Hampel
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.
Neurology 2007;69(24):2205-12.
2007: Malin E Andersson; Annica Sjölander; Niels Andreasen; Lennart Minthon; Oskar Hansson; Nenad Bogdanovic; Christina Jern; Katarina Jood; Anders Wallin; Kaj Blennow; Henrik Zetterberg
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.
International journal of molecular medicine 2007;20(2):233-9.
2007: M Salud García-Ayllón; María-Ximena Silveyra; Niels Andreasen; Stephen Brimijoin; Kaj Blennow; Javier Sáez-Valero
Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease.
Journal of neurochemistry 2007;101(6):1701-11.
2007: Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Lars Lannfelt; Stig Strid; Peter Annas; Hans Basun; Niels Andreasen
Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Neuroscience letters 2007;419(1):18-22.
2007: Bengt Winblad; Jeffrey L Cummings; Niels Andreasen; George Grossberg; Marco Onofrj; Carl Sadowsky; Stefanie Zechner; Jennifer Nagel; Roger Lane
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
International journal of geriatric psychiatry 2007;22(5):456-67.
2007: Asa K Wallin; Niels Andreasen; Sture Eriksson; Stellan Båtsman; Birgitta Nasman; Anne Ekdahl; Lena Kilander; Mikaela Grut; Marie Rydén; Anders Wallin; Mikael Jonsson; Hasse Olofsson; Elisabet Londos; Carina Wattmo; Maria Eriksdotter Jonhagen; Lennart Minthon
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Dementia and geriatric cognitive disorders 2007;23(3):150-60.
2007: Anja Hviid Simonsen; S F Hansson; U Ruetschi; James McGuire; Vladimir N Podust; Huw A Davies; P Mehta; Gunhild Waldemar; Henrik Zetterberg; Niels Andreasen; Anders Wallin; Kaj Blennow
Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
Dementia and geriatric cognitive disorders 2007;23(4):246-50.
2006: Erik Portelius; Henrik Zetterberg; Ulf Andreasson; Gunnar Brinkmalm; Niels Andreasen; Anders Wallin; Ann Westman-Brinkmalm; Kaj Blennow
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
Neuroscience letters 2006;409(3):215-9.
2006: Taher Darreh-Shori; Lennart Meurling; Tommy Pettersson; K Hugosson; Ewa Hellström-Lindahl; Niels Andreasen; L Minthon; agneta nordberg
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(11):1791-801.
2006: Henrik Zetterberg; Max Albert Hietala; Michael Jonsson; Niels Andreasen; Ewa Styrud; Ingvar Karlsson; Ake Edman; Cornel Popa; Abdullah Rasulzada; Lars-Olof Wahlund; Pankaj D Mehta; Lars Rosengren; Kaj Blennow; Anders Wallin
Neurochemical aftermath of amateur boxing.
Archives of neurology 2006;63(9):1277-80.
2006: Matthias Riemenschneider; Kaj Blennow; Stefan Wagenpfeil; Niels Andreasen; Jonathan A Prince; Simon Laws; hans förstl; Alexander Kurz
The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease.
Human mutation 2006;27(6):532-7.
2006: A-M Nilselid; Pia Davidsson; Katarina Nägga; Niels Andreasen; Pam Fredman; Kaj Blennow
Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms.
Neurochemistry international 2006;48(8):718-28.
2006: Linus Jönsson; Maria Eriksdotter-Jönhagen; Lena Kilander; Hilkka Soininen; Merja Hallikainen; Gunhild Waldemar; Harald Nygaard; Niels Andreasen; Bengt Winblad; Anders Wimo
Determinants of costs of care for patients with Alzheimer's disease.
International journal of geriatric psychiatry 2006;21(5):449-59.
2006: Mia E-L Blomqvist; Chandra Reynolds; Hagit Katzov; Lars Feuk; Niels Andreasen; Nenad Bogdanovic; Kaj Blennow; Anthony J Brookes; Jonathan A Prince
Towards compendia of negative genetic association studies: an example for Alzheimer disease.
Human genetics 2006;119(1-2):29-37.
2006: hugo vanderstichele; Karen De Vreese; Kaj Blennow; Niels Andreasen; C J M Sindic; Adrian Ivanoiu; Harald Hampel; Katharina Bürger; Lucilla Parnetti; Alessia Lanari; Alessandro Padovani; Monica DiLuca; Miriam Bläser; Annika Ohrfelt Olsson; Hans Pottel; Frank Hulstaert; Eugeen Vanmechelen
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(12):1472-80.
2006: Linus Jönsson; Niels Andreasen; Lena Kilander; Hilkka Soininen; Gunhild Waldemar; Harald Nygaard; Bengt Winblad; Maria Eriksdotter Jönhagen; Merja Hallikainen; Anders Wimo
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL.
Alzheimer disease and associated disorders 2006;20(1):49-55.
2006: Anders Wallin; Kaj Blennow; Niels Andreasen; Lennart Minthon
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Dementia and geriatric cognitive disorders 2006;21(3):131-8.
2006: Hagit Katzov; Anna M Bennet; Kina Höglund; Björn Wiman; Dieter Lütjohann; Anthony J Brookes; Niels Andreasen; Kaj Blennow; Ulf de Faire; Jonathan A Prince
Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels.
Journal of human genetics 2006;51(3):171-9.
2005: Katharina Buerger; Stefan J Teipel; Raymond Zinkowski; Trey Sunderland; Niels Andreasen; Kaj Blennow; Michael Ewers; John DeBernardis; Yong Shen; Daniel Kerkman; Yansheng Du; Harald Hampel
Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment.
Neuroscience letters 2005;391(1-2):48-50.
2005: Katharina Buerger; Michael Ewers; Niels Andreasen; Raymond Zinkowski; K Ishiguro; Eugeen Vanmechelen; Stefan J Teipel; Christian Graz; Kaj Blennow; Harald Hampel
Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study.
Neurology 2005;65(9):1502-3.
2005: Khalid Iqbal; Michael Flory; Sabiha Khatoon; Hilkka Soininen; Tuula Pirttila; Maarit Lehtovirta; Irina Alafuzoff; Kaj Blennow; Niels Andreasen; Eugeen Vanmechelen; Inge Grundke-Iqbal
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
Annals of neurology 2005;58(5):748-57.
2005: hugo vanderstichele; Geert De Meyer; Niels Andreasen; Vesna Kostanjevecki; Anders Wallin; Annika Olsson; Kaj Blennow; Eugeen Vanmechelen
Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
Clinical chemistry 2005;51(9):1650-60.
2005: Mia E-L Blomqvist; Katy Chalmers; Niels Andreasen; Nenad Bogdanovic; Gordon K Wilcock; Nigel J Cairns; Lars Feuk; Anthony J Brookes; Seth Love; Kaj Blennow; Pat Kehoe; Jonathan A Prince
Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
Neurobiology of aging 2005;26(6):795-802.
2005: Niels Andreasen; Kaj Blennow
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Clinical neurology and neurosurgery 2005;107(3):165-73.
2005: Annika Olsson; hugo vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
Clinical chemistry 2005;51(2):336-45.
2004: Henrik Zetterberg; Niels Andreasen; Kaj Blennow
Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.
Neuroscience letters 2004;367(2):194-6.
2004: Harald Hampel; Stefan J Teipel; T Fuchsberger; Niels Andreasen; J Wiltfang; M Otto; Yong Shen; Richard Dodel; Yansheng Du; Martin R Farlow; Hans-Jürgen Möller; Kaj Blennow; Katharina Buerger
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Molecular psychiatry 2004;9(7):705-10.
2004: Jonathan A Prince; Henrik Zetterberg; Niels Andreasen; Jan Marcusson; Kaj Blennow
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.
Neurology 2004;62(11):2116-8.
2004: Mia E-L Blomqvist; Peter A Silburn; Daniel D Buchanan; Niels Andreasen; Kaj Blennow; Nancy L Pedersen; Anthony J Brookes; George D Mellick; Jonathan A Prince
Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease.
Neurogenetics 2004;5(2):115-9.
2004: Annica Johansson; Hagit Katzov; Henrik Zetterberg; Lars Feuk; Boo Johansson; Nenad Bogdanovic; Niels Andreasen; Boris Lenhard; Anthony J Brookes; Nancy L Pedersen; Kaj Blennow; Jonathan A Prince
Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.
Human genetics 2004;114(6):581-7.
2004: Mia E-L Blomqvist; Niels Andreasen; Nenad Bogdanovic; Kaj Blennow; Anthony J Brookes; Jonathan A Prince
Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's disease.
Neuroscience letters 2004;358(3):220-2.
2004: Hagit Katzov; Katy Chalmers; Juni Palmgren; Niels Andreasen; Boo Johansson; Nigel J Cairns; Margaret Gatz; Gordon K Wilcock; Seth Love; Nancy L Pedersen; Anthony J Brookes; Kaj Blennow; Pat Kehoe; Jonathan A Prince
Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism.
Human mutation 2004;23(4):358-67.
2004: Pat Kehoe; Hagit Katzov; Niels Andreasen; Margaret Gatz; Gordon K Wilcock; Nigel J Cairns; Juni Palmgren; Ulf de Faire; Anthony J Brookes; Nancy L Pedersen; Kaj Blennow; Jonathan A Prince
Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease.
Human genetics 2004;114(5):478-83.
2004: Harald Hampel; Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Alexander Goernitz; Niels Andreasen; Magnus Sjoegren; John DeBernardis; Daniel Kerkman; Koichi Ishiguro; Hideto Ohno; Eugeen Vanmechelen; hugo vanderstichele; Cheryl McCulloch; Hans-Jurgen Moller; Peter Davies; Kaj Blennow
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Archives of general psychiatry 2004;61(1):95-102.
2003: Maja Puchades; Sara Folkesson Hansson; Carol L Nilsson; Niels Andreasen; Kaj Blennow; Pia Davidsson
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.
Brain research. Molecular brain research 2003;118(1-2):140-6.
2003: Niels Andreasen; Magnus Sjögren; Kaj Blennow
CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2003;4(4):147-55.
2003: Annika Olsson; Kina Höglund; Magnus Sjögren; Niels Andreasen; Lennart Minthon; Lars Lannfelt; Katharina Buerger; Hans-Jürgen Möller; Harald Hampel; Pia Davidsson; Kaj Blennow
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients.
Experimental neurology 2003;183(1):74-80.
2003: Elisabeth Tarkowski; Niels Andreasen; Andrej Tarkowski; Kaj Blennow
Intrathecal inflammation precedes development of Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry 2003;74(9):1200-5.
2003: Magnus Sjögren; Niels Andreasen; Kaj Blennow
Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
Clinica chimica acta; international journal of clinical chemistry 2003;332(1-2):1-10.
2003: Javier Sáez-Valero; Lisa R Fodero; M Sjögren; Niels Andreasen; Serena Amici; Virgilio Gallai; hugo vanderstichele; E Vanmechelen; Lucilla Parnetti; Kaj Blennow; David Small
Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Journal of neuroscience research 2003;72(4):520-6.
2003: Javier Sáez-Valero; Mercedes Costell; Magnus Sjögren; Niels Andreasen; Kaj Blennow; Juan M Luque
Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease.
Journal of neuroscience research 2003;72(1):132-6.
2003: Niels Andreasen; Eugeen Vanmechelen; hugo vanderstichele; Pia Davidsson; Kaj Blennow
Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Acta neurologica Scandinavica. Supplementum 2003;179():47-51.
2002: Pia Davidsson; Magnus Sjögren; Niels Andreasen; Maria Lindbjer; Carol L Nilsson; Ann Westman-Brinkmalm; Kaj Blennow
Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins.
Brain research. Molecular brain research 2002;109(1-2):128-33.
2002: Lucilla Parnetti; Serena Amici; Alessia Lanari; C Romani; Cinzia Antognelli; Niels Andreasen; L Minthon; P Davidsson; Hans Pottel; Kaj Blennow; Virgilio Gallai
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2002;23 Suppl 2():S95-6.
2002: Katharina Buerger; Stefan J Teipel; Raymond Zinkowski; Kaj Blennow; Hiroyuki Arai; Rolf Engel; Klaus Hofmann-Kiefer; Cheryl McCulloch; U Ptok; Reinhard Heun; Niels Andreasen; John DeBernardis; Daniel Kerkman; H- J Moeller; Peter Davies; Harald Hampel
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.
Neurology 2002;59(4):627-9.
2002: Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Mark B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
Archives of neurology 2002;59(8):1267-72.
2002: Niels Andreasen; Kaj Blennow
Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.
Peptides 2002;23(7):1205-14.
2002: Pia Davidsson; Ann Westman-Brinkmalm; Carol L Nilsson; Maria Lindbjer; Linda Paulson; Niels Andreasen; Magnus Sjögren; Kaj Blennow
Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients.
Neuroreport 2002;13(5):611-5.
2001: Eugeen Vanmechelen; hugo vanderstichele; Frank Hulstaert; Niels Andreasen; L Minthon; Bengt Winblad; P Davidsson; Kaj Blennow
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
Mechanisms of ageing and development 2001;122(16):2005-11.
2001: M Sjögren; hugo vanderstichele; Hans Agren; Olof Zachrisson; Mikael Edsbagge; Carsten Wikkelsø; Ingmar Skoog; Anders Wallin; Lars-Olof Wahlund; J Marcusson; Katarina Nägga; Niels Andreasen; P Davidsson; Eugeen Vanmechelen; Kaj Blennow
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.
Clinical chemistry 2001;47(10):1776-81.
2001: Niels Andreasen; Johan Gottfries; Eugeen Vanmechelen; hugo vanderstichele; P Davidson; Kaj Blennow; L Rosengren; K Blennow
Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry 2001;71(4):557-8.
2001: Kaj Blennow; B Lind; E Andersson; Niels Andreasen
[CSF-analyses in clinical diagnosis of Creutzfeldt-Jakob disease. A literature review and three cases from routine clinical practice].
Läkartidningen 2001;98(20):2446-51.
2001: Pia Davidsson; Kaj Blennow; Niels Andreasen; B Eriksson; Lennart Minthon; C Hesse
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Neuroscience letters 2001;300(3):157-60.
2001: Niels Andreasen; Lennart Minthon; Pia Davidsson; Eugeen Vanmechelen; hugo vanderstichele; Bengt Winblad; Kaj Blennow
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Archives of neurology 2001;58(3):373-9.
2001: C Hesse; L Rosengren; Niels Andreasen; Pia Davidsson; hugo vanderstichele; Eugeen Vanmechelen; Kaj Blennow
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.
Neuroscience letters 2001;297(3):187-90.
2001: Magnus Sjögren; C Hesse; Hans Basun; G Köl; H Thostrup; Lena Kilander; Jan Marcusson; Ake Edman; Anders Wallin; Ingvar Karlsson; M Troell; G Wachtmaister; A Ekdahl; Hasse Olofsson; A Sandström; Niels Andreasen; Lennart Minthon; Kaj Blennow
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
Journal of neural transmission (Vienna, Austria : 1996) 2001;108(4):451-8.
2000: hugo vanderstichele; E Van Kerschaver; C Hesse; Pia Davidsson; M A Buyse; Niels Andreasen; L Minthon; Anders Wallin; Kaj Blennow; Eugeen Vanmechelen
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2000;7(4):245-58.
2000: Eugeen Vanmechelen; hugo vanderstichele; Pia Davidsson; E Van Kerschaver; B Van Der Perre; M Sjögren; Niels Andreasen; Kaj Blennow
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.
Neuroscience letters 2000;285(1):49-52.
2000: C Hesse; H Larsson; Pam Fredman; Lennart Minthon; Niels Andreasen; Pia Davidsson; Kaj Blennow
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.
Neurochemical research 2000;25(4):511-7.
2000: Kaj Blennow; Anne Ricksten; Jonathan A Prince; Anthony J Brookes; T Emahazion; Carina Wasslavik; Nenad Bogdanovic; Niels Andreasen; Stellan Båtsman; Jan Marcusson; Katarina Nägga; Anders Wallin; Björn Regland; Hasse Olofsson; C Hesse; Pia Davidsson; Lennart Minthon; A Jansson; Lars Palmqvist; Lars Rymo
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(8-9):1065-79.
1999: Niels Andreasen; Lennart Minthon; A Clarberg; Pia Davidsson; Johan Gottfries; Eugeen Vanmechelen; hugo vanderstichele; Bengt Winblad; Kaj Blennow
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.
Neurology 1999;53(7):1488-94.
1999: Niels Andreasen; Lennart Minthon; Eugeen Vanmechelen; hugo vanderstichele; Pia Davidsson; Bengt Winblad; Kaj Blennow
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.
Neuroscience letters 1999;273(1):5-8.
1999: Niels Andreasen; C Hesse; Pia Davidsson; Lennart Minthon; Anders Wallin; Bengt Winblad; hugo vanderstichele; Eugeen Vanmechelen; Kaj Blennow
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.
Archives of neurology 1999;56(6):673-80.
1999: Niels Andreasen; Kaj Blennow; C Sjödin; Bengt Winblad; K Svärdsudd
Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Piteå Dementia Project.
Neuroepidemiology 1999;18(3):144-55.
1998: Niels Andreasen; Eugeen Vanmechelen; André Van de Voorde; Pia Davidsson; C Hesse; S Tarvonen; Ismo Räihä; Leif B Sourander; Bengt Winblad; Kaj Blennow
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
Journal of neurology, neurosurgery, and psychiatry 1998;64(3):298-305.
1996: Niels Andreasen; S Eriksson; I Karlsson; B Lindahl; M Lund; agneta nordberg; A Wimo; Bengt Winblad; R Astrand
[More accurate diagnosis could identify patients suitable for tacrine therapy].
Läkartidningen 1996;93(13):1200.